Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab versus cetuximab in previously treated wild-type KRAS metastatic colorectal cancer
NL-OMON36817Phase 3Withdrawn
- Sponsor
- Amgen
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) comparing Panitumumab with Cetuximab (2 arms). Primary endpoint: Overall survival. Planned start Jan 2010; status: withdrawn.
02
Drugs
panitumumabcetuximab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON36817.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36817.